30 results about "Antibody screens" patented technology

The invention relates to a cell strain for screening affinity maturation of an antibody and a use method thereof. The cell strain is stable in expression of a target antibody by virtue of a RMCE technology. Combined with a somatic hypermutation technology of activation-induced cytidine deaminase, the cell strain for screening affinity maturation of the antibody is relatively high in efficiency and the affinity of the antibody can be improved to a great extent within a relatively short time and screening turns.

The invention discloses a bovine viral diarrhea virus differential detection test strip and a preparation method thereof, which are used for rapid and sensitive detection of BVDV antibodies. The test strip is composed of a support base plate, a coated adsorption material layer, a protein marker bearing material layer, a sample buffer material layer, a liquid absorbent material layer, and an outer protective material; the coated absorbent material is provided with a test line and a quality control line The protein label of the test strip is labeled with colloidal gold; the protein used for the protein label is the phage monoclonal combined with the BVDV antibody obtained by screening from the phage polypeptide library; the polypeptide epitope expressed by the phage monoclonal is LTPHKHHKHLHA. The preparation method comprises the preparation of gold-labeled phage monoclonal, the preparation of gold-labeled pads, the preparation of nitrocellulose membrane, and the assembly of various parts to obtain the finished product. The invention can obtain detection results within ten minutes, is fast and sensitive, has low cost, is simple to operate, and is easy to be popularized and applied in production and scientific research at the grassroots level.

The present invention provides an anti-BCMA antigen-binding fragment and its application. The heavy chain variable region of the antigen-binding fragment of the anti-B cell mature antigen includes: the complementarity determining region 1 shown in SEQ ID NO.1, the complementarity determining region 2 shown in SEQ ID NO.2 and the complementarity determining region shown in SEQ ID NO.3. Complementarity determining region 3 shown. In the present invention, the antibody screened by the phage display antigen-binding fragment library has a specific CDR region, and the obtained antibody can specifically bind to the BCMA antigen, and has good affinity, and its K a (1 / Ms) is 2.81E+06, K d (1 / s) is 4.36E‑04, K D (M) is 1.55E-10; it is used as an antigen-binding domain to construct chimeric antigen receptors and CAR-T cells, which has broad application prospects in the immunotherapy of multiple myeloma.

The invention discloses a fully human antagonistic antibody screened from a ScFv phage antibody library with THY-1 / CD90 as a target, the fully human antagonistic antibody is a single-chain antibody, and the heavy chain DNA sequence of the fully human antagonistic antibody As shown in SEQ ID NO:1, the light chain DNA sequence is shown in SEQ ID NO:2, the heavy chain amino acid sequence is shown in SEQ ID NO:3, and the light chain amino acid sequence is shown in SEQ ID NO:4. According to the above technical scheme, the fully human antagonistic antibody targeting THY-1 / CD90 is screened from the human ScFv phage antibody library, and its DNA sequence and amino acid sequence are respectively determined. The fully human antagonistic antibody obtained by this method has the target Specificity towards THY‑1 / CD90. The antibody produced in this way can overcome the shortcomings of hybridoma technology to produce antibodies, and can also achieve the purpose of high-throughput and rapid screening of antibodies, and the price is low.

The present invention provides a nanobody against B cell maturation antigen and its application. The anti-B cell maturation antigen nanobody is BCMA-12, and the heavy chain variable region of the BCMA-12 includes: complementarity determining region 1 shown in SEQ ID NO.1, complementarity determining region 1 shown in SEQ ID NO.2 Determining region 2 and complementarity determining region 3 shown in SEQ ID NO.3. In the present invention, the antibody screened by the phage display nanobody library has a specific CDR region, and the obtained antibody can specifically bind to the BCMA antigen with good affinity; it is used as the antigen binding domain to construct a chimeric antigen receptor and CAR-T It has obvious killing activity to BCMA-positive tumor cells. Therefore, the nanobody has broad application prospects in the immunotherapy of multiple myeloma.

The present invention provides a chimeric antigen receptor against human CAIX antigen and its application; the chimeric antigen receptor consists of a scFv recognizing human CAIX antigen, a hinge region, a transmembrane region and an intracellular signal domain in sequence. A new anti-human CAIX scFv was screened by a hybridoma antibody screening system, and the scFv was concatenated with the Hinge and transmembrane region of human CD8, the intracellular signaling domain of 4‑1BB and CD3ζ to construct a new chimeric antigen receptor scFv‑CD8‑4‑1BB‑CD3ζ, with higher specificity and better tumor killing effect.

The present invention provides an anti-CD123 antibody and use thereof, the antibody includes a heavy chain variable region; the heavy chain variable region includes CDR1 shown in SEQ ID NO: 1, CDR2 shown in SEQ ID NO: 2, and CDR3 shown in SEQ ID NO:3. The antibodies screened from the camel VHH immune library of the present invention have the CDR regions shown in SEQ ID NOs: 1 to 3, and the antibodies formed by combining with the framework region FRs have strong affinity for CD123, and the chimeric antigen receptors, chimeric antigen receptors and chimeric antigen receptors constructed thereby Antigen receptor immune cells have significant cytotoxicity to CD123 positive cells and have broad application prospects in the field of tumor therapy.